Mental health and substance use associated with hospitalization among people with laboratory confirmed diagnosis of COVID-19 in British Columbia: a population-based cohort study

Authors:

1. Héctor Alexander Velásquez García, MD, MS, MPH, PhD^{1,2}
2. James Wilton, MSc^{1,2}
3. Kate Smolina, DPhil^{1,2}
4. Mei Chong, MSc¹
5. Drona Rasali, BVSc, MS, PhD^{1,2}
6. Michael Otterstatter, PhD^{1,2}
7. Caren Rose, PhD^{1,2}
8. Natalie Prystajecky, PhD¹
9. Samara David, MSc³
10. Eleni Galanis, MD, MPH^{1,2}
11. Geoffrey McKee, MD, MPH¹
12. Mel Krajden, MD^{1,4}
13. Naveed Zafar Janjua, MBBS, MSc, DrPH^{1,2,5}

Affiliations:

1. British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
2. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
3. Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada.
4. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
5. Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada

Corresponding Author:

Naveed Zafar Janjua, MBBS, MSc, DrPH
 Executive Director, Data and Analytic Services, BC Centre for Disease Control
 Clinical Professor, School of Population and Public Health
 University of British Columbia
 655 West 12th Avenue
 Vancouver, BC V5Z 4R4
 Tel: 604-707-2514
 Fax: 604-707-2401
 Email: naveed.janjua@bccdc.ca

Word count of manuscript: 2,429

Abstract

Background: This study identified factors associated with hospital admission among people with laboratory-diagnosed COVID-19 cases in British Columbia.

Methods: This study was performed using the BC COVID-19 Cohort, which integrates data on all COVID-19 cases, hospitalizations, medical visits, emergency room visits, prescription drugs, chronic conditions and deaths. The analysis included all laboratory-diagnosed COVID-19 cases in British Columbia as of January 15th, 2021. We evaluated factors associated with hospital admission using multivariable Poisson regression analysis with robust error variance.

Findings: From 56,874 COVID-19 cases included in the analyses, 2,298 were hospitalized. Models showed significant association of the following factors with increased hospitalization risk: male sex (adjusted risk ratio (aRR)=1.27; 95%CI=1.17-1.37), older age (p-trend <0.0001 across age groups with a graded increase in hospitalization risk with increasing age [aRR 30-39 years=3.06; 95%CI=2.32-4.03, to aRR 80+years=43.68; 95%CI=33.41-57.10 compared to 20-29 years-old]), asthma (aRR=1.15; 95%CI=1.04-1.26), cancer (aRR=1.19; 95%CI=1.09-1.29), chronic kidney disease (aRR=1.32; 95%CI=1.19-1.47), diabetes (treated without insulin aRR=1.13; 95%CI=1.03-1.25, requiring insulin aRR=5.05; 95%CI=4.43-5.76), hypertension (aRR=1.19; 95%CI=1.08-1.31), injection drug use (aRR=2.51; 95%CI=2.14-2.95), intellectual and developmental disabilities (aRR=1.67; 95%CI=1.05-2.66), problematic alcohol use (aRR=1.63; 95%CI=1.43-1.85), immunosuppression (aRR=1.29; 95%CI=1.09-1.53), and schizophrenia and psychotic disorders (aRR=1.49; 95%CI=1.23-1.82). Among women of reproductive age, in addition to age and

comorbidities, pregnancy (aRR=2.69; 95%CI=1.42-5.07) was associated with increased risk of hospital admission.

Interpretation: Older age, male sex, substance use, intellectual and developmental disability, chronic comorbidities, and pregnancy increase the risk of COVID-19-related hospitalization.

Funding: BC Centre for Disease Control, Canadian Institutes of Health Research.

Research in context

Evidence before this study: Factors such as older age, social inequities and chronic health conditions have been associated to severe COVID-19 illness. Most of the evidence comes from studies that don't include all COVID-19 diagnoses in a jurisdiction), focusing on in-hospital mortality. In addition, mental illness and substance use were not evaluated in these studies. This study assessed factors associated with hospital admission among people with laboratory-diagnosed COVID-19 cases in British Columbia.

Added value of this study: In this population-based cohort study that included 56,874 laboratory-confirmed COVID-19 cases, older age, male sex, injection drug use, problematic alcohol use, intellectual and developmental disability, schizophrenia and psychotic disorders, chronic comorbidities and pregnancy were associated with the risk of hospitalization. Insulin-dependent diabetes was associated with higher risk of hospitalization, especially in the subpopulation younger than 40 years. To the best of our knowledge this is the first study reporting this finding, (insulin use and increased risk of COVID-19-related death has been described previously).

Implications of all the available evidence: Prioritization of vaccination in population groups with the above mentioned risk factors could reduce COVID-19 serious outcomes. The findings indicate the presence of the syndemic of substance use, mental illness and COVID-19, which deserve special public health considerations.

Introduction

COVID-19 caused by SARS-CoV-2, affecting millions of people globally, resulted in a spectrum of health outcomes among those affected. Presentations range from asymptomatic and mild illnesses to severe disease that requires hospitalization with varying needs for more intensive levels of care.¹⁻³

Elevated levels of hospitalization and need for healthcare surge capacity, particularly intensive care unit (ICU), have been key drivers of pandemic response planning and contributed to societal disruption.³ Studies have identified various demographic factors (e.g. being older in age, male) and chronic comorbidities (e.g. diabetes, cardiovascular disease (CVD), hypertension) as risk factors for hospitalization and other severe outcomes;² however, most studies were conducted on patients presenting at hospitals. There are very few population-based studies investigating risk factors in the entire population of COVID-19 diagnosed individuals in a jurisdiction. This can lead to potential selection bias when characterizing risk factors. Older age has been identified as the strongest risk factor for severe disease along with various comorbidities,⁴ however, very few studies investigated relationship of substance use, intellectual disabilities and role of insulin dependent diabetes with the risk of severe outcomes.^{5,6}

In addition, the clinical threshold to admit to hospital may vary across countries, especially early in the pandemic; hence, knowledge of factors associated with hospitalization in the Canadian context is important. Population-level hospitalization risk factor studies are also particularly essential for prioritization of interventions to reduce health system burden and maintain hospital capacity. In this study, we identified factors

associated with hospital admission among people with COVID-19 infection in British Columbia (BC).

Methods

Study population

The study used data from the BC COVID-19 Cohort (BCC19C), which integrates data on all individuals tested for COVID-19 in BC, including all lab-diagnosed cases, COVID-19 hospital and ICU census, medical visits, other hospitalizations, emergency room visits, prescription drugs, chronic conditions and mortality (Supplementary data, Appendix A, Table S1). That BCC19C was established as a public health surveillance system under the BCCDC's public health mandate. This study was reviewed and approved by the Behavioral Research Ethics Board at the University of British Columbia (approval # H20-02097).

The study population for this analysis included individuals who tested positive for SARS-CoV-2 by real-time reverse transcription–polymerase chain reaction (RT-PCR), from January 26th, 2020 to January 15th, 2021. The outcome of interest was hospitalization as the measure of case severity related to COVID-19 infection, defined as hospital admission in a BC acute care facility within 14 days after a positive SARS-CoV-2 test^{7–9}. Patients residing in long term care facilities were excluded from the analyses as their transfer to hospitals was variable over time and across local regions. For women of reproductive age (15-49 years), hospital admissions related to COVID-19 were considered as such only if no obstetric-related hospitalization code was found in DAD, within 14 days of hospital admission (Appendix D).

Comorbidities: We examined the following chronic conditions: Alzheimer/dementia, asthma, chronic heart disease (CHD: acute myocardial infarct, angina, heart failure,

ischemic myocardial infarct), chronic obstructive pulmonary disease (COPD), cirrhosis, chronic kidney disease (CKD), depression, diabetes (categorized as no-diabetes, treated without insulin, and requiring insulin), epilepsy, gout, hypertension, stroke (ischemic, haemorrhagic, transitory ischemic attack), mood and anxiety disorders, osteoarthritis, osteoporosis, parkinsonism, rheumatoid arthritis, substance use disorder, injection drug use (IDU), problematic alcohol use, cancer, immunosuppression, intellectual and developmental disabilities (IDD), and schizophrenia and psychotic disorders (SZP). Variable definitions and diagnostic codes are detailed in Supplementary data (Appendix C).

Statistical analysis

We described the baseline characteristics of participants including age, sex, and pregnancy status.

We evaluated risk factors associated with hospital admission, calculating risk ratios through multivariable Poisson regression models with robust error variance.¹⁰ For age, analyses were conducted as continuous as well as categorized into groups. To assess population differences across time, the cohort was stratified according to two waves or time periods: January 26th to August 1st, 2020, and August 2nd, 2020 to January 15th, 2021. Sensitivity analyses were performed by 1) stratifying the population by age group, and 2) by restricting the outcome to hospitalizations lasting more than two days to address severity. All statistical analyses were performed using R version 4.0.2.

Results

The analysis included 56,874 COVID-19 cases diagnosed up to January 15th, 2021; 2,298 (4.0%) of them were admitted to the hospital. A slightly higher proportion of people diagnosed as COVID-19 positive were male (51.2%), with much higher proportion among people requiring hospital admission (58.5% vs. 50.9) (Table 1). The median age of COVID-19 cases was 35 years (IQR:24-50), while that of people requiring hospital admission was nearly twice that (66 years; IQR:53-78). The proportion of hospitalized cases increased with each 10 year age-groups increment, from 0.2% in the youngest subpopulation (<20 years) to 34.2% in the eldest group (80+ years) (RR=66.96; 95%CI=52.35-85.65). Pregnant women were more likely to be hospitalized than women who were not (2.5% vs. 1.1%).

Chronic comorbidities as risk factors:

The proportion of comorbidities among hospitalized individuals was higher than in those who did not require hospitalization (Table 1), including hypertension (54.1 vs. 14%), depression (38.3 vs. 21.7%), diabetes (35.8 vs. 8.3%), osteoarthritis (27.3 vs. 6.6%), CHD (26.9 vs. 4.4%), cancer (26.8 vs. 9.9%), CKD (23.5 vs. 3.0%), asthma (20.1 vs. 13.1%), substance use disorder (13.7 vs. 4.3%), problematic alcohol use (13.6 vs. 4.1%), heart failure (11.7 vs. 1.1%), COPD (11.5 vs. 1.5%), IDU (10 vs. 3.8%), and immunosuppression (6.0 vs. 2.2%).

In the adjusted multivariable Poisson regression model (Table 2; Figure 1), older age (p-trend <0.0001 across age groups with a graded increase in hospitalization risk with increasing age [aRR 30-39 years=3.06; 95%CI=2.32-4.03, to aRR 80+years=43.68;

95%CI=33.41-57.10 compared to 20-29 years-old]), male sex (aRR=1.27; 95%CI=1.17-1.37), asthma (aRR=1.15; 95%CI=1.04-1.26), cancer (1.19; 95%CI=1.09-1.29), CKD (RR=1.32; 95%CI=1.19-1.47), diabetes (treated without insulin aRR=1.13; 95%CI=1.03-1.25, requiring insulin aRR=5.05; 95%CI=4.43-5.76), hypertension (aRR=1.19; 95%CI=1.08-1.31), immunosuppression(1.30; 95%CI=1.10-1.54), IDU (aRR=2.51; 95%CI=2.14-2.95), IDD (aRR=1.67; 95%CI=1.05-2.66), problematic alcohol use (aRR=1.63; 95%CI=1.43-1.85), and SZP (aRR=1.49; 95%CI=1.23-1.82), were associated with increased hospitalization risk. The analysis by time period (Supplemental Tables S2, S3) did not show any remarkable differences in risk factors.

Among women of reproductive age(Table 3), pregnancy (aRR=3.05; 95%CI=1.86-5.07), older age(p-trend <0.0001 across age groups; RR=2.32; 95%CI=1.54-3.48 comparing 40-49 to 20-29 years-old), asthma (aRR=1.80; 95%CI=1.29-2.52), diabetes (treated without insulin aRR=2.39; 95%CI=1.46-3.89, requiring insulin aRR=31.89; 95%CI=16.78-60.60), hypertension (aRR=2.02; 95%CI=1.29-3.16), IDU (aRR=3.97; 95%CI=2.44-6.43), and problematic alcohol use (aRR=3.05; 95%CI=1.86-5.02), were factors significantly associated with higher risk of hospital admission.

In the analysis stratified by age (Table 4), diabetes, and problematic alcohol use were associated with hospitalization across all age groups, with higher risk among younger groups that decreased with older age. Male sex, cancer and hypertension were associated with higher risk of hospital admission among those over 40 years of age. In the analysis restricted to hospitalizations lasting more than two days (Supplemental Table S4) did not show different findings compared with the overall analysis.

Discussion

In this large population-based analysis of all COVID-19 cases in BC, older age, male sex, pregnancy, and numerous chronic co-morbidities and other health-related conditions such as substance use were associated with increased hospitalization risk. Older age was the strongest predictor of hospital admission with risk increasing more than 40 fold for the oldest group compared to the 20-29 years. In addition to well-characterized co-morbidities, we found that injection drug use,¹¹ problematic alcohol use, schizophrenia, and psychotic disorders,¹² as well as intellectual and developmental disability, were independently associated with higher risk of hospitalization, highlighting syndemic of substance use, mental illness and COVID-19. Our findings have important implications for the vaccination program to prevent COVID-19 infection and severe outcomes and subsequently reduce hospital burden and mortality and were used to inform COVID-19 vaccination program in BC.¹³

Our analysis confirms findings from other studies evaluating risk factors for severe COVID-19 outcomes, although ours is one of the few population-based analyses(i.e., includes all COVID-19 diagnoses in a jurisdiction). Most evaluations have also focused on in-hospital mortality, rather than morbidity. In addition to older age and male sex, a wide range of co-morbidities were associated with a higher risk of hospitalization, reflecting similar findings from other studies.^{7, 14–19} These co-morbidities included asthma, chronic kidney disease, diabetes, cancer, immunosuppression and substance use. Associations between most co-morbidities and hospitalization were stronger at younger ages, highlighting the overall low risk of hospitalization among younger people without pre-existing co-morbidities, despite the findings that the hospitalization risk

increased with age in the overall population. The highest risk was observed in people of older ages with co-morbidities with incremental risk by age. Several biological studies have identified sex and age differences in biological pathways related to SARS-CoV-2 infection and support our findings.^{20–22} Pregnancy has been previously identified as a potential risk factor for ICU admission^{23,24} and severe disease,²⁵ but most studies have been limited to pregnant women who were already hospitalized (including for non-COVID-19 reasons such as childbirth).^{23,26} This finding could be in part the result of a lower clinical threshold for hospitalization of pregnant patients.

Insulin-dependent diabetes, in particular in the stratum younger than 40 years, was associated with higher risk of hospitalization. To our knowledge this is the first report observing this phenomenon, though insulin use and increased risk of COVID-19-related death was described earlier. Further research is needed to better characterize this finding.

Our analysis also highlights the intersection between the two ongoing public health emergencies in BC: the COVID-19 and the opioid overdose epidemics. The COVID-19 pandemic has exacerbated the pre-existing opioid epidemic, through mechanisms such as disruption of harm reduction services,²⁷ with BC experiencing a record high number of illicit drug toxicity deaths in 2020.²⁸ Our findings indicate that individuals at high risk of overdose, as indicated by IDU, are also at higher risk of COVID-19 hospitalization. This is the first study investigating impact of COVID-19 on people who inject drugs. IDU was the second co-morbidity most strongly associated with hospitalization in our analysis. Similarly problematic alcohol use, and schizophrenia and psychotic disorders were also associated with higher risk of hospitalization. The higher risk of COVID-19-related

hospitalization highlights the syndemic of substance use, mental illness and COVID-19.

Many underlying social conditions such as unstable housing, lower socioeconomic status and many co-occurring co-morbidities may have exacerbated the effect of COVID-19 infection among these individuals. Prioritization of vaccination for this population group could reduce disparities and increased risk of hospitalization.

Our analysis had several limitations. We relied on administrative data to identify patient characteristics and co-morbidities; this may have led to some level of misclassification. Similarly, for the same reason, it is not possible to evaluate clinical severity of the event leading to hospital admission. Further, we did not have information on socioeconomic status, race/ethnicity, and obesity. Also, given that the evaluation of the COVID-19 status depends on the BC diagnostic testing guidelines (varying over time to focus on symptom-based assessment since April 21st, 2020),²⁹ selective ascertainment of symptomatic cases is expected, resulting in exclusion of asymptomatic cases.³⁰

In conclusion, older age, male sex, pregnancy, and various comorbidities and health-conditions including substance use were associated with higher risk of hospital admission in this population-based analysis. These findings have informed the COVID-19 vaccination program rollout in BC and will be useful for informing the prioritization of vaccination in other jurisdictions to prevent infection and severe outcomes.¹³ In addition, these findings will also inform monitoring of individual patients by their healthcare providers at higher risk of severe outcomes. Finally there is a need for further characterizing syndemics of substance use, mental illness and COVID-19.

Contributors

HAVG and NZJ contributed to study conception, design, and analyzed data. NZJ, NP and MK were involved in funding acquisition. NJ, SD, EG, JW, MC, and MK were involved in data acquisition. All authors contributed to data interpretation. HAVG was responsible for the first draft of the manuscript. All authors contributed to critical revision of the manuscript. All authors had access to and verified all the data and accept responsibility for the decision to submit for publication. The database for the study has been accessed and verified by HAVG and NZJ. All authors had full access to all the data and had final responsibility for the decision to submit for publication.

Data sharing

The study is based on data contained in various provincial registries and databases. Access to data could be requested through the BC Centre for Disease Control Institutional Data Access for researchers who meet the criteria for access to confidential data. Requests for the data may be sent to datarequest@bccdc.ca.

Declaration of interests

MK has received grant funding via his institution from Roche Molecular Systems, Boehringer Ingelheim, Merck, Siemens Healthcare Diagnostics and Hologic Inc. All other authors have no potential conflicts of interest to declare.

Funding

This work was supported by BC Centre for Disease Control and the Canadian Institutes of Health Research [Grant # VR5-172683 and OV4-170361].

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Disclaimer

All inferences, opinions, and conclusions drawn in this report are those of the authors, and do not reflect the opinions or policies of the Data Steward(s).

Acknowledgements

We acknowledge the assistance of the Provincial Health Services Authority, BC Centre for Disease Control, BC Ministry of Health and Regional Health Authority staff involved in data access, procurement, and management. We gratefully acknowledge the residents of British Columbia whose data are integrated in the British Columbia COVID-19 Cohort (BCC19C).

Figure 1 – Multivariable model for factors associated with COVID-19-related hospitalization in British Columbia

Table 1 – Distribution of characteristics in the BC COVID-19 cohort (confirmed cases, N= 56,874)[§], according to hospitalization status

Variable	Category	Total* N=56,874	Non-hospitalized ^o N=54,576	Hospitalized ^o N=2,298	Hospitalized row %	Crude incidence rate ratio (95% conf. interv.)	P†
Sex	Female	27,769 (48.8%)	26,816 (49.1%)	953 (41.5%)	3.4%	Reference	<0.0001
	Male	29,105 (51.2%)	27,760 (50.9%)	1,345 (58.5%)	4.6%	1.35 (1.24-1.46)	
Age (years)	N/A	36 (28)§	35 (26)§	66 (25)§	-	1.07 (1.06-1.07)	<0.0001
Age group[‡]	<20 years	7,683 (13.5%)	7,665 (14.0%)	18 (0.8%)	0.2%	0.45 (0.27-0.77)	0.0031
	20-29 years	13,490 (23.7%)	13,421 (24.6%)	69 (3.0%)	0.5%	Reference	-
	30-39 years	10,681 (18.8%)	10,507 (19.3%)	174 (7.6%)	1.6%	3.18 (2.41-4.20)	<0.0001
	40-49 years	8,818 (15.8%)	8,604 (15.8%)	214 (9.3%)	2.4%	4.74 (3.62-6.22)	<0.0001
	50-59 years	7,565 (13.3%)	7,201 (13.2%)	364 (15.8%)	4.8%	9.41 (7.28-12.15)	<0.0001
	60-69 years	4,793 (8.4%)	4,330 (7.9%)	463 (20.1%)	9.7%	18.89 (14.70-24.27)	<0.0001
	70-79 years	2,425 (4.3%)	1,915 (3.5%)	510 (22.2%)	21.0%	41.12 (32.10-52.67)	<0.0001
	80+ years	1,419 (2.5%)	933 (1.7%)	486 (21.1%)	34.2%	66.96 (52.35-85.65)	<0.0001
Pregnant (female population, ages 15 to 49; n=17,693)	No	16,638 (94.0%)	16,457 (94.1%)	181 (86.6%)	1.1%	Reference	-
	Yes	398 (2.2%)	388 (2.2%)	10 (4.8%)	2.5%	2.31 (1.23-4.33)	0.0091
	Unknown	657 (3.7%)	639 (3.7%)	18 (8.6%)	2.7%	2.52 (1.56-4.06)	0.0002
Angina	No	55,915 (98.3%)	53,850 (98.7%)	2,065 (89.9%)	3.7%	Reference	<0.0001
	Yes	959 (1.7%)	726 (1.3%)	233 (10.1%)	24.3%	6.58 (5.84-7.41)	
Chronic heart disease¹	No	53,840 (94.7%)	52,161 (95.6%)	1,679 (73.1%)	3.1%	Reference	<0.0001
	Yes	3,034 (5.3%)	2,415 (4.4%)	619 (26.9%)	20.4%	6.54 (6.01-7.12)	
Heart failure	No	56,003 (98.5%)	53,975 (98.9%)	2,028 (88.3%)	3.6%	Reference	<0.0001
	Yes	871 (1.5%)	601 (1.1%)	270 (11.7%)	31.0%	8.56 (7.68-8.54)	
Hypertension	No	48,009 (84.4%)	46,955 (86.0%)	1,054 (45.9%)	2.2%	Reference	<0.0001
	Yes	8,865 (15.6%)	7,621 (14.0%)	1,244 (54.1%)	14.0%	6.39 (5.91-6.92)	
Ischemic heart disease	No	54,139 (95.2%)	52,378 (96.0%)	1,761 (76.6%)	3.3%	Reference	<0.0001
	Yes	2,735 (4.8%)	2,198 (4.0%)	537 (23.4%)	19.6%	6.04 (5.52-6.59)	
Myocardial infarct	No	56,273 (98.9%)	54,109 (99.1%)	2,164 (94.2%)	3.8%	Reference	<0.0001
	Yes	601 (1.1%)	467 (0.9%)	134 (5.8%)	22.3%	5.80 (4.97-6.77)	
Immunosuppression²	No	55,541 (97.7%)	53,380 (97.8%)	2,161 (94.0%)	3.9%	Reference	<0.0001
	Yes	1,333 (2.3%)	1,196 (2.2%)	137 (6.0%)	10.3%	2.64 (2.24-3.11)	
Rheumatoid arthritis	No	56,198 (98.8%)	53,998 (98.9%)	2,200 (95.7%)	3.9%	Reference	<0.0001
	Yes	676 (1.2%)	578 (1.1%)	98 (4.3%)	14.5%	3.70 (3.07-4.47)	
Depression	No	44,541 (78.3%)	43,124 (79.0%)	1,417 (61.7%)	3.2%	Reference	<0.0001
	Yes	12,333 (21.7%)	11,452 (21.0%)	881 (38.3%)	7.1%	2.25 (2.07-2.44)	
Intellectual and developmental disability³	No	56,444 (99.2%)	54,177 (99.3%)	2,267 (98.7%)	4.0%	Reference	0.0008
	Yes	430 (0.8%)	399 (0.7%)	31 (1.3%)	7.2%	1.79 (1.28-2.53)	

Mood and anxiety disorders	No	41,590 (73.1%)	40,322 (73.9%)	1,268 (55.2%)	3.0%	Reference	<0.0001
	Yes	15,284 (26.9%)	14,254 (26.1%)	1,030 (44.8%)	6.7%	2.21 (2.04-2.39)	
Schizophrenia and psychotic disorders	No	56,112 (98.7%)	53,927 (98.8%)	2,185 (95.1%)	3.9%	Reference	<0.0001
	Yes	762 (1.3%)	649 (1.2%)	113 (4.9%)	14.8%	3.81 (3.20-4.53)	
Diabetes	No	51,487 (90.5%)	50,011 (91.6%)	1,476 (64.2%)	2.9%	Reference	-
	Non-insulin	5,141 (9.1%)	4,541 (8.3%)	600 (26.1%)	11.7%	4.07 (3.72-4.46)	
	Insulin ⁵	246 (0.4%)	24 (0.0%)	222 (9.7)	90.2%	31.48 (29.50-33.59)	
Gout	No	55,707 (97.9%)	53,622 (98.3%)	2,085 (90.7%)	3.7%	Reference	<0.0001
	Yes	1,167 (2.1%)	964 (1.7%)	213 (9.3%)	18.3%	4.88 (4.29-5.55)	
Chronic kidney disease⁴	No	54,686 (96.2%)	52,928 (97.0%)	1,758 (76.5%)	3.2%	Reference	<0.0001
	Yes	2,188 (3.8%)	1,648 (3.0%)	540 (23.5%)	24.7%	7.68 (7.04-8.37)	
Osteoarthritis	No	52,645 (92.6%)	50,975 (93.4%)	1,670 (72.7%)	3.2%	Reference	<0.0001
	Yes	4,229 (7.4%)	3,601 (6.6%)	628 (27.3%)	14.8%	4.68 (4.29-5.10)	
Osteoporosis	No	55,831 (98.2%)	53,771 (98.5%)	2,060 (89.6%)	3.7%	Reference	<0.0001
	Yes	1,043 (1.8%)	805 (1.5%)	238 (10.4%)	22.8%	6.18 (5.49-6.97)	
Alzheimer / dementia	No	56,624 (99.6%)	54,411 (99.7%)	2,213 (93.3%)	3.9%	Reference	<0.0001
	Yes	250 (0.4%)	165 (0.3%)	85 (3.7%)	34.0%	8.70 (7.28-10.39)	
Epilepsy	No	56,465 (99.3%)	54,216 (99.3%)	2,249 (97.9%)	4.0%	Reference	<0.0001
	Yes	409 (0.7%)	360 (0.7%)	49 (2.1%)	12.0%	3.01 (2.31-3.92)	
Parkinsonism	No	56,806 (99.9%)	54,534 (99.9%)	2,272 (98.9%)	4.0%	Reference	<0.0001
	Yes	68 (0.1%)	42 (0.1%)	26 (1.1%)	38.2%	9.56 (7.05-12.97)	
Stroke (combined)⁵	No	56,571 (99.5%)	54,351 (99.6%)	2,220 (96.6%)	3.9%	Reference	<0.0001
	Yes	303 (0.5%)	225 (0.4%)	78 (3.4%)	25.7%	6.56 (5.39-7.98)	
Stroke (hemorrhagic)	No	56,817 (99.9%)	54,528 (99.9%)	2,289 (99.6%)	4.0%	Reference	<0.0001
	Yes	57 (0.1%)	48 (0.1%)	9 (0.4%)	15.8%	3.92 (2.15-7.15)	
Stroke (ischemic)	No	56,705 (99.7%)	54,453 (99.8%)	2,252 (98.0%)	4.0%	Reference	<0.0001
	Yes	169 (0.3%)	123 (0.2%)	46 (2.0%)	27.2%	6.85 (5.34-8.80)	
Transitory ischemic attack	No	56,773 (99.8%)	54,504 (99.9%)	2,269 (98.7%)	4.0%	Reference	<0.0001
	Yes	101 (0.2%)	72 (0.1%)	29 (1.3%)	28.7%	7.18 (5.27-9.79)	
Asthma	No	49,270 (86.6%)	47,435 (86.9%)	1,835 (79.9%)	3.7%	Reference	<0.0001
	Yes	7,604 (13.4%)	7,141 (13.1%)	463 (20.1%)	6.1%	1.63 (1.48-1.81)	
Chronic obstructive pulmonary disease	No	55,800 (98.1%)	53,767 (98.5%)	2,033 (88.5%)	3.6%	Reference	<0.0001
	Yes	1,074 (1.9%)	809 (1.5%)	265 (11.5%)	24.7%	6.77 (6.05-7.58)	
Injection drug use⁶	No	54,574 (96.0%)	52,506 (96.2%)	2,068 (90.0%)	3.8%	Reference	<0.0001
	Yes	2,300 (4.0%)	2,070 (3.8%)	230 (10.0%)	10.0%	2.64 (2.32-3.00)	
Problematic alcohol use⁷	No	54,322 (95.5%)	52,336 (95.9%)	1,986 (86.4%)	3.7%	Reference	<0.0001
	Yes	2,552 (4.5%)	2,240 (4.1%)	312 (13.6%)	12.2%	3.34 (2.99-3.74)	

Cancer⁸	No	50,865 (89.4%)	49,182 (90.1%)	1,683 (73.2%)	3.3%	Reference	<0.0001
	Yes	6,009 (10.6%)	5,394 (9.9%)	615 (26.8%)	10.2%	3.09 (2.83-3.38)	
Cirrhosis⁹	No	56,635 (99.6%)	54,402 (99.7%)	2,233 (97.2%)	3.9%	Reference	<0.0001
	Yes	239 (0.4%)	174 (0.3%)	65 (2.8%)	27.2%	6.90 (5.58-8.52)	

⁸ Individuals residing in long term care facilities were excluded.

* Number of participants (proportion within variable).

⁹ Number of participants (proportion within hospitalization status subgroup).

† Bivariate Poisson regression with robust error variance (Wald's test).

‡ P-trend <0.0001 (age groups assessed as pseudo-continuous values).

§ Median (interquartile range).

¹ Combination of acute myocardial infarct, chronic heart failure, and ischemic heart disease.

² Sundaram ME, Calzavara A, Mishra S, Kustra R, Chan AK, Hamilton MA, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. *CMAJ* 2021;193:E723–34. <https://doi.org/10.1503/CMAJ.202608>.

³ Based on ICD-9/ICD-10 codes from: Manitoba Centre for Health Policy. Concept: Intellectual Disability (ID) (Mental Retardation) / Developmental Disability (DD) / Developmental Disorders. University of Manitoba, 2020.07.09, <http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1365>. Accessed on 2021.02.08.

⁴ Assessed via “renal disease” ICD-9/ICD-10 codes from group 14 of Elixhauser Comorbidity Score, in DAD, MSP & NACRS records.

⁵ Combination of hemorrhagic stroke, stroke (hospitalized), transitory ischemic attack (hospitalized), and ischemic stroke.

⁶ Janjua NZ, Islam N, Kuo M, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. *Int J Drug Policy*. 2018;55:31-39. <https://doi.org/10.1016/j.drugpo.2018.02.001>.

⁷ Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). *EBioMedicine* 2016;12:189–95. <https://doi.org/10.1016/j.ebiom.2016.08.035>.

⁸ Assessed via “lymphoma”, “metastatic cancer”, and “solid tumor without metastasis” ICD-9/ICD-10 codes from groups 18, 19 & 20 of Elixhauser Comorbidity Score, in DAD, MSP & NACRS records.

⁹ Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). *EBioMedicine* 2016;12:189–95. <https://doi.org/10.1016/j.ebiom.2016.08.035>.

Table 2 - Factors associated with hospitalization status in multivariable Poisson regression analysis with robust error variance among confirmed cases, BC COVID-19 Cohort[Ⓜ]

Variable	Category	2020.JAN.26–2021.JAN.15 (N=56,874; hospitalized=2,298)	
		aRR (95%CI)*	P†
Sex (vs. female)	Male	1.27 (1.17-1.37)	<0.0001
Age[‡] (Reference group: 20-29 years)	<20 years	0.51 (0.30-0.85)	0.0103
	30-39 years	3.06 (2.32-4.03)	<0.0001
	40-49 years	4.45 (3.40-5.82)	<0.0001
	50-59 years	8.05 (6.22-10.41)	<0.0001
	60-69 years	14.98 (11.58-19.37)	<0.0001
	70-79 years	28.15 (21.64-36.61)	<0.0001
	80+ years	43.68 (33.41-57.10)	<0.0001
Asthma		1.15 (1.04-1.26)	0.0049
Cancer¹		1.19 (1.09-1.29)	0.0001
Chronic kidney disease²		1.32 (1.19-1.47)	<0.0001
Diabetes (vs. non-diabetic)	Non-insulin	1.13 (1.03-1.25)	0.0112
	Insulin ³	5.05 (4.43-5.76)	<0.0001
Hypertension		1.19 (1.08-1.31)	0.0007
Immunosuppression⁴		1.30 (1.10-1.54)	0.0019
Injection drug use⁵		2.51 (2.14-2.95)	<0.0001
Intellectual and developmental disability⁶		1.67 (1.05-2.66)	0.0307
Problematic alcohol use⁷		1.63 (1.43-1.85)	<0.0001
Schizophrenia and psychotic disorders		1.49 (1.23-1.82)	<0.0001

[Ⓜ] Individuals residing in long term care facilities were excluded.

* Incidence rate ratios adjusted for the variables present in the table.

† Wald's test.

‡ P-trend >0.0001 (age groups assessed as pseudo-continuous values)

¹ Assessed via “lymphoma”, “metastatic cancer”, and “solid tumor without metastasis” ICD-9/ICD-10 codes from groups 18, 19 & 20 of Elixhauser Comorbidity Score, in DAD, MSP & NACRS records.

² Assessed via “renal disease” ICD-9/ICD-10 codes from group 14 of Elixhauser Comorbidity Score, in DAD, MSP & NACRS records.

³ Any type; includes concomitant treatment with antihyperglycemic agents.

⁴ Sundaram ME, Calzavara A, Mishra S, Kustra R, Chan AK, Hamilton MA, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. CMAJ 2021;193:E723–34. <https://doi.org/10.1503/CMAJ.202608>.

⁵ Janjua NZ, Islam N, Kuo M, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018;55:31-39. <https://doi.org/10.1016/j.drugpo.2018.02.001>.

⁶ Based on ICD-9/ICD-10 codes from: Manitoba Centre for Health Policy. Concept: Intellectual Disability (ID) (Mental Retardation) / Developmental Disability (DD) / Developmental Disorders. University of Manitoba, 2020.07.09, <http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1365>. Accessed on 2021.02.08.

⁷ Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine 2016;12:189–95. <https://doi.org/10.1016/j.ebiom.2016.08.035>.

Table 3 - Factors associated with hospitalization status in multivariable Poisson regression analysis with robust error variance among women of reproductive age (15-49 years-old), BC COVID-19 Cohort[‡]

Variable	Category	2020.JAN.26–2021.JAN.15 (N=17,036; hospitalized=191)	
		aRR (95%CI)*	P†
Age^{**} (Reference group: 20-29 years)	<20 years	0.24 (0.06-0.95)	0.0424
	30-39 years	1.99 (1.35-2.94)	0.0005
	40-49 years	2.32 (1.54-3.48)	<0.0001
Asthma		1.80 (1.29-2.52)	0.0005
Diabetes (vs. non-diabetic)	Non-insulin	2.39 (1.46-3.89)	0.0005
	Insulin ¹	31.89 (16.78-60.60)	<0.0001
Hypertension		2.02 (1.29-3.16)	0.0020
Injection drug use²		3.97 (2.44-6.43)	<0.0001
Pregnancy		2.69 (1.42-5.07)	0.0023
Problematic alcohol use³		3.05 (1.86-5.02)	<0.0001

[‡] Individuals residing in long term care facilities were excluded.

[‡] 657 observations with missing pregnancy status were removed from original sample (N=17,693).

* Incidence rate ratios adjusted for the variables present in the table.

** P-trend >0.0001 (age groups assessed as pseudo-continuous values)

† Wald's test.

¹ Any type; includes concomitant treatment with antihyperglycemic agents.

² Janjua NZ, Islam N, Kuo M, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. *Int J Drug Policy*. 2018;55:31-39.

<https://doi.org/10.1016/j.drugpo.2018.02.001>.

³ Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). *EBioMedicine* 2016;12:189–95.

<https://doi.org/10.1016/j.ebiom.2016.08.035>.

Table 4- Factors associated with hospitalization status in multivariable Poisson regression analysis with robust error variance among confirmed cases, BC COVID-19 Cohort[‡], stratified by age group.

Variable		Age group							
		All age groups ^o (N=56,874; hospitalized=2,298)		< 40 years (N=31,854; hospitalized=261)		40-59 years (n=16,383; hospitalized=578)		60+ years (n=8,637; hospitalized=1,459)	
		aRR (95%CI)*	P†	aRR (95%CI)*	P†	aRR (95%CI)*	P†	aRR (95%CI)*	P†
Sex (male vs. female)		1.27 (1.17-1.37)	<0.0001	0.99 (0.77-1.27)	0.93	1.46 (1.24-1.72)	<0.0001	1.26 (1.15-1.38)	<0.0001
Asthma		1.15 (1.04-1.26)	0.0049	1.10 (0.78-1.54)	0.59	1.41 (1.16-1.71)	0.0005	1.10 (0.98-1.23)	0.09
Cancer ¹		1.19 (1.09-1.29)	0.0001	1.47 (0.99-2.17)	0.054	1.24 (1.00-1.54)	0.0459	1.31 (1.19-1.44)	<0.0001
Chronic kidney disease ²		1.32 (1.19-1.47)	<0.0001	2.68 (1.22-5.90)	0.0141	1.32 (0.97-1.80)	0.08	1.70 (1.53-1.88)	<0.0001
Diabetes (vs. non-diabetic)	Non-insulin	1.13 (1.03-1.25)	0.0112	2.03 (0.98-4.17)	0.055	1.62 (1.31-1.99)	<0.0001	1.01 (0.91-1.12)	0.87
	Insulin ³	5.05 (4.43-5.76)	<0.0001	20.29 (4.69-87.90)	<0.0001	19.30 (14.66-25.40)	<0.0001	3.94 (3.52-4.41)	<0.0001
Hypertension		1.19 (1.08-1.31)	0.0007	1.87 (0.98-3.57)	0.057	1.46 (1.21-1.75)	<0.0001	1.31 (1.18-1.46)	<0.0001
Immunosuppression ⁴		1.30 (1.10-1.54)	0.0019	2.56 (1.67-3.94)	<0.0001	1.30 (0.95-1.76)	0.10	1.14 (0.93-1.38)	0.21
Injection drug use ⁵		2.51 (2.14-2.95)	<0.0001	2.95 (1.78-4.90)	<0.0001	2.55 (1.97-3.30)	<0.0001	1.01 (0.76-1.32)	0.97
Intellectual and developmental disability ⁶		1.67 (1.05-2.66)	0.0307	1.17 (0.56-2.42)	0.68	4.28 (2.29-8.01)	<0.0001	1.21 (0.71-2.04)	0.49
Problematic alcohol use ⁷		1.63 (1.43-1.85)	<0.0001	2.84 (1.72-4.72)	<0.0001	1.62 (1.26-2.10)	0.0002	1.53 (1.30-1.79)	<0.0001
Schizophrenia and psychotic disorders		1.49 (1.23-1.82)	<0.0001	2.33 (1.40-3.87)	0.0012	1.19 (0.80-1.76)	0.38	1.56 (1.21-2.00)	0.0005

[‡] Individuals residing in long term care facilities were excluded.

* Incidence rate ratios adjusted for the variables present in the table.

^o Adjusted for also for age (as categorical groups from Table 2; not shown).

† Wald's test.

¹ Assessed via "lymphoma", "metastatic cancer", and "solid tumor without metastasis" ICD-9/ICD-10 codes from groups 18, 19 & 20 of Elixhauser Comorbidity Score, in DAD, MSP & NACRS records.

² Assessed via "renal disease" ICD-9/ICD-10 codes from group 14 of Elixhauser Comorbidity Score, in DAD, MSP & NACRS records.

³ Any type; includes concomitant treatment with antihyperglycemic agents.

⁴ Sundaram ME, Calzavara A, Mishra S, Kustra R, Chan AK, Hamilton MA, et al. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. *CMAJ* 2021;193:E723-34. <https://doi.org/10.1503/CMAJ.202608>.

⁵ Janjua NZ, Islam N, Kuo M, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. *Int J Drug Policy*. 2018;55:31-39. doi:10.1016/j.drugpo.2018.02.001.

⁶ Based on ICD-9/ICD-10 codes from: Manitoba Centre for Health Policy. Concept: Intellectual Disability (ID) (Mental Retardation) / Developmental Disability (DD) / Developmental Disorders. University of Manitoba, 2020.07.09, <http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1365>. Accessed on 2021.02.08.

⁷ Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). *EBioMedicine* 2016;12:189-95. <https://doi.org/10.1016/j.ebiom.2016.08.035>.

References

1. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med* 2020;8:506–17. [https://doi.org/10.1016/S2213-2600\(20\)30161-2](https://doi.org/10.1016/S2213-2600(20)30161-2).
2. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *Lancet Diabetes Endocrinol* 2020;8:823–33. [https://doi.org/10.1016/S2213-8587\(20\)30271-0](https://doi.org/10.1016/S2213-8587(20)30271-0).
3. Carenzo L, Costantini E, Greco M, Barra FL, Rendiniello V, Mainetti M, et al. Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy. *Anaesthesia* 2020;75:928–34. <https://doi.org/10.1111/anae.15072>.
4. Himmels JPW, Borge TC, Brurberg KG, Gravningen KM, Feruglio SL, Berild JD. COVID-19 and risk factors for hospital admission, severe disease and death 3rd update. Norwegian Institute of Public Health 2020.11.15. https://www.fhi.no/en/publ/2020/COVID19-and-risk-factors-for-hospital-admission-severe-disease-and-death-3rd_update/. Accessed 2021.05.18
5. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry* 2021;26:30–9. <https://doi.org/10.1038/s41380-020-00880-7>.
6. Baillargeon J, Polychronopoulou E, Kuo YF, Raji MA. The impact of substance use disorder on COVID-19 outcomes. *Psychiatr Serv* 2021;72:578–81. <https://doi.org/10.1176/appi.ps.202000534>.

7. Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk Factors for Coronavirus Disease 2019 (COVID-19)—Associated Hospitalization: COVID-19—Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clin Infect Dis 2020. <https://doi.org/10.1093/cid/ciaa1419>.
8. Owusu D, Kim L, O'Halloran A, Whitaker M, Piasecki AM, Reingold A, et al. Characteristics of Adults aged 18–49 Years without Underlying Conditions Hospitalized with Laboratory-Confirmed COVID-19 in the United States, COVID-NET — March–August 2020. Clin Infect Dis 2020. <https://doi.org/10.1093/cid/ciaa1806>.
9. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021;397:2461–2. [https://doi.org/10.1016/s0140-6736\(21\)01358-1](https://doi.org/10.1016/s0140-6736(21)01358-1).
10. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol 2004;159:702–6. <https://doi.org/10.1093/aje/kwh090>.
11. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry 2021;26:30–9. <https://doi.org/10.1038/s41380-020-00880-7>.
12. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. The Lancet Psychiatry 2021. [https://doi.org/10.1016/S2215-0366\(21\)00232-7](https://doi.org/10.1016/S2215-0366(21)00232-7).
13. Government of British Columbia. COVID-19 Immunization Plan. <https://www2.gov.bc.ca/gov/content/covid-19/vaccine/plan>. Accessed on 2021.06.27.

14. Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA, et al. Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. *Journals Gerontol - Ser A Biol Sci Med Sci* 2020;75:2224–30. <https://doi.org/10.1093/gerona/glaa183>.
15. Galbadage T, Peterson BM, Awada J, Buck AS, Ramirez DA, Wilson J, et al. Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes. *Front Med* 2020;7:348. <https://doi.org/10.3389/fmed.2020.00348>.
16. O'Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age. *J Ovarian Res* 2020;13:137. <https://doi.org/10.1186/s13048-020-00734-4>.
17. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. *BMJ* 2020;369. <https://doi.org/10.1136/bmj.m1966>.
18. van Gerwen M, Alsen M, Little C, Barlow J, Genden E, Naymagon L, et al. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. *J Med Virol* 2021;93:907–15. <https://doi.org/10.1002/jmv.26337>.
19. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. *PLoS One* 2021;16:e0247461. <https://doi.org/10.1371/journal.pone.0247461>.

20. Haitao T, Vermunt J V., Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, et al. COVID-19 and Sex Differences: Mechanisms and Biomarkers. *Mayo Clin Proc* 2020;95:2189–203. <https://doi.org/10.1016/j.mayocp.2020.07.024>.
21. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* 2020;588:315–20. <https://doi.org/10.1038/s41586-020-2700-3>.
22. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. *J Clin Invest* 2020;130:6141–50. <https://doi.org/10.1172/JCI142004>.
23. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1641–7. <https://doi.org/10.15585/mmwr.mm6944e3>.
24. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are clinical outcomes worse for pregnant women at ≥ 20 weeks' gestation infected with coronavirus disease 2019? A multicenter case-control study with propensity score matching. *Am J Obstet Gynecol* 2020;223:764–8. <https://doi.org/10.1016/j.ajog.2020.07.045>.
25. Oakes MC, Kernberg AS, Carter EB, Foeller ME, Palanisamy A, Raghuraman N, et al. Pregnancy as a risk factor for severe coronavirus 2019 (COVID-19) disease using standardized clinical criteria. *Am J Obstet Gynecol MFM* 2021;3:100319. <https://doi.org/10.1016/j.ajogmf.2021.100319>.

26. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. *BMJ* 2020;370:3320. <https://doi.org/10.1136/bmj.m3320>.
27. BC Centre for Disease Control. Overdose Response Indicators. <https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/statistical/illicit-drug.pdf>. Accessed 2021.05.06.
28. British Columbia Coroner's Service. Illicit drug toxicity deaths in BC: January 1, 2011 – March 31, 2021. Minister of Public Safety and Solicitor General, Burnaby, BC 2021.04.29. <https://www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/statistical/illicit-drug.pdf>. Accessed 2021.05.06.
29. BC Centre for Disease Control. Phases of COVID-19 testing in BC. <http://www.bccdc.ca/health-info/diseases-conditions/covid-19/testing/phases-of-covid-19-testing-in-bc>. 2021 (accessed 2021.03.11).
30. Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. *PLoS One* 2020;15:e0241536. <https://doi.org/10.1371/journal.pone.0241536>.